James Paul Rickey, Chief Financial Officer at Braveheart Bio, Inc. (BRVE), bought 27,777 shares at $18.00 ($500K) on 2026-08-07, disclosed to the SEC on 2026-08-07.
Chief Financial Officer James Paul Rickey purchased $500k of stock at $18.00, marking the largest insider purchase in the company's history and signaling confidence in the post-IPO momentum. This rare reversal from a zero-selling streak by a high-grade insider suggests the market may be overlooking the stock's recent strength.
The stock is currently trading at $31.82, representing a 10.68% premium to its 52-week low of $28.75 and hitting a new 52-week high of $31.82, indicating strong recent price action following the August 11 IPO listing.
1) IPO completion and Nasdaq Composite Index inclusion on August 11, 2026; 2) The company filed a large shelf registration on August 11, 2026, to provide flexibility for future capital raises; 3) Five insiders bought shares in the last 30 days, creating a cluster of buying momentum.
The stock is currently trading at its 52-week high, which may limit further upside if the market corrects after the initial IPO euphoria, and the company has filed a shelf registration indicating potential future dilution.
Something here stands out, but not much.
| Filing → |
| ALPN | SELL | 2023-12-18 | $2.0M | — | Filing → |
| ALPN | SELL | 2023-12-06 | $2.3M | — | Filing → |
| ALPN | SELL | 2023-12-01 | $11K | — | Filing → |